Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation

Leukemia Research

Volumn 38, Issue 7, 2014, Pages 822-829

  Savickiene, Jurate ^a   Treigyte, Grazina ^a   Stirblyte, Ieva ^a   Valiuliene, Giedre ^a   Navakauskiene, Ruta ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Acute myeloid leukemia; BIX 01294; Cell cycle arrest; Differentiation; Histone modifications

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIZATION; GENE EXPRESSION; GRANULOCYTE; HISTONE MODIFICATION; HL 60 CELL LINE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NB4 CELL LINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

ACUTE MYELOID LEUKEMIA; BIX-01294; CELL-CYCLE ARREST; DIFFERENTIATION; HISTONE MODIFICATIONS;

AZEPINES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTOCOMPATIBILITY ANTIGENS; HISTONE-LYSINE N-METHYLTRANSFERASE; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; QUINAZOLINES; TRETINOIN;

EID: 84902087529     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.04.003     Document Type: Article

References (32)

1. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002, 2:198-209.
2. Tachibana M., Sugimoto K., Fukushima T., Shinkai I. Set-domain-containing protein, G9a, is a novel lysine- preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Mol Biol 2001, 276:25309-25317.
3. Schneider R., Bannister A.J., Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci 2002, 27:396-402.
4. Kim K.C., Geng L., Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 2003, 63:7619-7623.
5. Albert M., Helin K. Histone methyltransferases in cancer. Semin Cell Dev Biol 2010, 21:209-220.
6. Kondo Y., Shen L., Suzuki S., Kurokawa T., Masuko K., Tanaka Y., et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007, 37:974-983.
7. Cho H.S., Kelly J.D., Hayami S., Toyokawa G., Takawa M., Yoshimatsu M., et al. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 2011, 13:676-684.
8. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006, 66:6361-6369.
9. Kondo Y., Shen L., Ahmed S., Boumber Y., Sekido Y., Haddad B.R., et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS ONE 2008, 3(4):e2037.
10. Chang Y., Zhang X., Horton J.R., Upadhyay A.K., Spannhoff A., Liu J., et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol 2009, 16:312-317.
11. Hinchcliffe E.H., Sluder G. It takes two to tango: understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev 2001, 15:1167-1181.
12. Savickiene J., Treigyte G., Jazdauskaite A., Borutinskaite V.V., Navakauskiene R. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling. Cell Biol Int 2012, 36:1067-1078.
13. Hurley C.K. Electrophoresis of histones: a modified Panyim and Chalkley system for slab gels. Anal Biochem 1977, 80:624-626.
14. Drexler H.G., Quentmeier H., MacLeod R.A., Uphoff C.C., Hu Z.B. Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. Leuk Res 1995, 19:681-691.
15. Barber N., Belov L., Christopheron R.I. All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukemias. Leuk Res 2008, 32:315-322.
16. Janku F., McConkey D.J., Hong D.S., Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011, 8:528-539.
17. Konopleva M., Elstner E., McQueen T.J., Tsao T., Sudarikov A., Hu W., et al. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004, 3:1249-1262.
18. Maskey D., Yousefi S., Schmid I., Zlobec I., Perren A., Friis R., et al. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun 2013, 4:2130-2144.
19. Gan Q., Huang J., Zhou R., Niu J., Zhu X., Wang J., et al. PPAR{gamma} accelerates cellular senescence by inducing p16INK4{alpha} expression in human diploid fibroblasts. J Cell Sci 2008, 121:2235-2245.
20. Han L., Zhou R., Niu J., McNutt M.A., Wang P., Tong T. SIRT1 is regulated by a PPAR{γ}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res 2010, 38:7458-7471.
21. Lu M., Kwan T., Yu C., Chen F., Freedman B., Schafer JM,et al Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005, 280:6742-6751.
22. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001, 7:680-686.
23. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
24. Castedo M., Perfettini J-L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837.
25. Dohi T., Beltrami E., Wall N.R., Plescia J., Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004, 114:1117-1127.
26. Chang B.D., Xuan Y., Broude E.V., Zhu H., Schott B., Fang J., et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18:4808-4818.
27. Vernier M., Bourdeau V., Gaumont-Leclerc M.F., Moiseeva O., Bégin V., Saad F., et al. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev 2011, 25:41-50.
28. Lekstrom-Himes J.A. The role of C/EBP (epsilon) in the terminal stages of granulocyte differentiation. Stem Cells 2001, 19:125-133.
29. Truong B.T., Lee Y.J., Lodie T.A., Park D.J., Perrotti D., Watanabe N., et al. CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 2003, 101:1141-1148.
30. Estève P.O., Chin H.G., Smallwood A., Feehery G.R., Gangisetty O., Karpf A.R., et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 2006, 20:3089-30103.
31. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006, 66:3541-3549.
32. Kubicek S., O'Sullivan R.J., August E.M., Hickey E.R., Zhang Q., Teodoro M.L., et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007, 25:473-481.